The FDA Comment Window on Compounded GLP-1s Closes July 30 — Not June 29

Deadlines get extended. The extension is a separate document.

That is the whole story, and it is why a live public-participation window has spent three weeks looking closed. FDA published the proposal on May 1 (91 FR 23431) with a 60-day comment period. On June 15 an outside group — the Collaborative for Evidence-Based Medicines — asked for 60 more days, arguing the original window was too short to engage the clinical, public-health and legal questions properly. On June 26 FDA granted half: thirty days, to July 30, reasoning that it balanced adequate time against delaying agency action.

We checked the docket itself rather than trusting the write-ups. As of July 17, 2026 the notice is recorded as open for comment, closing 11:59 p.m. ET on July 30, with 1,492 comments already posted to it.

The trap, if you go looking

The Federal Register's own page for the extension currently renders a sidebar reading that comments are no longer being accepted, and a metadata card giving a comment-close date of May 1. Both are wrong — artifacts of that site's automated widgets reading a stale field, sitting inches from the legal text that says July 30 in plain English.

A primary source is not an infallible source, and this story is built out of that lesson. FDA's own press release put the original deadline at June 29; the Federal Register notice it was announcing said June 30. They disagreed by a day from the start, and the extension is measured from the notice, not the press release.

While we are correcting the record

Two framing errors run through almost all coverage of this proposal, and they change what the action can actually reach. It is a notice, not a rule. And it proposes not to include the three substances on the 503B Bulks List — none of which was ever on it. Nothing was removed, delisted or excluded, because nothing was listed. FDA's own press headline uses the word "exclude", which is where most of the confusion begins.

The practical consequence is that this action does not directly touch a 503A pharmacy, which never relied on the Bulks List. What ended routine 503A compounding was the shortage resolution in 2025. Mass-market compounded GLP-1 ended in May 2025, not in 2026 — a distinction worth having if you are trying to work out what happened to your own supply.

What FDA asked to hear about

The extension notice is specific: FDA encourages comments addressing the clinical-need standard provided by the statute and the agency's reasoning in the May notice. Its stated basis is that no clinical need exists for outsourcing facilities to compound these three from bulk, and it has been explicit that affordability and insurance access do not constitute clinical need. Whether that reading of the statute is right is the question actually on the table.

Comments are public and permanent, including any name placed in the body. After July 30 there is a final determination and no second window. We take no position on what anyone should file — only that a window this widely reported as shut is worth knowing is open.

Related on Grey Peptides